Oryzon Genomics - Positive ALICE readouts pave way in AML
Oryzon Genomics has presented the top-line results of its Phase IIa ALICE trial investigating its lead oncology LSD1 inhibitor iadademstat in...
683 Views
Oryzon Genomics - IND granted for collaborative Phase II trial
Oryzon Genomics announced that it has received FDA investigational new drug (IND) approval for the initiation of a collaborative Phase II trial...
19 Views
Oryzon Genomics - Clinical ramp in Q3; several catalysts approaching
Oryzon Genomics reported Q322 results that are largely in line with our expectations. The clinical ramp up of its key assets, iadademstat and...
302 Views
Oryzon Genomics - Encouraging safety data in PORTICO
Oryzon Genomics has announced promising preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial at the 10th European...
680 Views
Oryzon Genomics - Preclinical collaboration in orphan disease
Oryzon Genomics has announced that it is has entered into a partnership with the Charcot-Marie-Tooth Research Foundation (CMTRF). The collaboration...
667 Views